Alzheimer Disease, Cognition Disorder
Conditions
Keywords
Alzheimer's Disease, Cognition Disorder
Brief summary
The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers. ACD856 will be administered orally.
Interventions
DRUGACD856
Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
DRUGPlacebo
Placebo oral solution
Sponsors
AlzeCure Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Signed and dated informed consent prior to any study-mandated procedure. * Willing and able to comply with study requirements. * Healthy male or female adults of non-childbearing potential aged ≥ 18 and ≤ 65 years at screening. * Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 at screening. * Only subjects of non-childbearing potential may be included in the study. Male subjects with partners of childbearing potential must be willing to use condoms, be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner, as well as refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. * Clinically acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
Exclusion criteria
* Any exposure to ACD856 in the past. * Treatment with another investigational drug within 3 months prior to or during the study. * Positive screen for drugs of abuse or a positive alcohol result at screening or admission to the clinic. * Clinically relevant findings in laboratory parameters, ECG or vital signs at screening. * Current smokers or subjects who use nicotine products. * History of alcohol abuse or excessive intake of alcohol. * History of, or current use of, anabolic steroids. * Excessive caffeine consumption. * Plasma donation or blood donation prior to screening. * Any planned night shift work within the duration of the study, from 48 h prior to randomisation until follow-up. * Any planned major surgery within the duration of the study. * Evidence of an active infection that requires treatment with antibiotics within 2 weeks of planned dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of adverse events (AEs) | 16 days | Number and percentage of subjects with adverse events (AEs). |
| Clinically significant changes in 12-lead ECGs | 16 days | Number of subjects and percentage of subjects with clinically significant changes in 12-lead ECGs |
| Clinically significant changes in vital signs | 16 days | Number of subjects and percentage of subjects with clinically significant changes in vital signs or stool frequency |
| Clinically significant changes in hematology, clinical chemistry, coagulation and/or urinalysis parameters | 16 days | Number of subjects and percentage of subjects with clinically significant changes in any safety laboratory assessments. |
| Clinically significant changes in physical examinations | 16 days | Number of subjects and percentage of subjects with clinically significant changes in physical examinations |
| GAD-7 | 16 days | Change from baseline of GAD-7 |
| PHQ-9 | 16 days | Change from baseline of PHQ-9 |
| C-SSRS | 16 days | Change from baseline of C-SSRS |
| Prolactin | 10 days | Change from baseline of prolactin levels |
Countries
Sweden
Outcome results
None listed